Darryl Rideout

Dr. Rideout joined Tonix as EVP of Experimental Chemistry in 2020. He also worked with Tonix from 2012 to 2020 as a consultant and provider of discovery chemistry services through his CRO (Focus Synthesis). Prior to starting Focus Synthesis, Dr. Rideout directed chemistry at Structural Bioinformatics and other small pharma companies. He held an associate faculty position at Scripps Research Institute in La Jolla, CA, and post-doctoral positions at Rockefeller University and Harvard.

Dr. Rideout’s areas of expertise include drug discovery chemistry, early-stage preclinical development, supportive chemistry for clinical trials, and diagnostic discovery chemistry. He has developed the chemistry for synthesis and stability analysis for a nonaddictive pain medication candidate in late-stage clinical trials. He developed the chemistry behind commercial clinical diagnostic agents for vitamin D deficiency and bile acid malabsorption. Indications for his past and current drug candidates include diabetes, cancer, autoimmune disorders, emotionality, exposure to ionizing radiation, and major depressive disorder. His methodology encompasses alternative solutions to difficult problems in drug design, synthesis, purification, metabolism, and formulation, as well as the introduction of leading-edge technologies. At Scripps Research Institute, he developed self-assembling cytotoxins, a target-selective drug synergism approach.

Dr. Rideout received his Ph.D. in Bioorganic Chemistry from Columbia University with Ronald Breslow, and an AB in Chemistry from Princeton, Summa Cum Laude.